Yang Cao

TL;DR: It is demonstrated that phospho-tau (p-t Tau) antibodies, PHF6 and PHF13, can prevent the induction of tau pathology in primary neuron cultures and provides evidence supporting the use of t Tau immunotherapy as a potential treatment option for AD and other tauopathies.

TL;DR: It is shown that the Aβ rise depends on the β-secretase-derived C-terminal fragment of APP (βCTF or C99 levels with low levels with high levels causing rises, while the N-terminally truncated form of Aβ, known as “p3,” formed by α- secretase cleavage, did not exhibit a rise.

TL;DR: A class of isonicotinamides that are potent, highly kinase-selective GSK-3 inhibitors are presented, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD.

TL;DR: The excellent correlation between brain Aβ40 andγ-secretase occupancy suggests that a positron emission tomography ligand for γ- secretase could be a valuable biomarker to determine whether γ -secretase inhibitors bind to their target in humans.

TL;DR: The ability of locked nucleic acid (LNA)-modified antisense oligonucleotides (ASOs) to selectively knock down mutant myosin transcripts by targeting single-nucleotide polymorphisms (SNPs) is investigated and suggests that SNP-targeting ASOs are a promising therapeutic modality for treating cardiac pathology.